Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stefan Schandelmaier is active.

Publication


Featured researches published by Stefan Schandelmaier.


JAMA | 2014

Prevalence, Characteristics, and Publication of Discontinued Randomized Trials

Benjamin Kasenda; Erik von Elm; John J. You; Anette Blümle; Yuki Tomonaga; Ramon Saccilotto; Alain Amstutz; Theresa Bengough; Joerg J. Meerpohl; Mihaela Stegert; Kari A.O. Tikkinen; Ignacio Neumann; Alonso Carrasco-Labra; Markus Faulhaber; Sohail Mulla; Dominik Mertz; Elie A. Akl; Dirk Bassler; Jason W. Busse; Ignacio Ferreira-González; Francois Lamontagne; Alain Nordmann; Viktoria Gloy; Heike Raatz; Lorenzo Moja; Rachel Rosenthal; Shanil Ebrahim; Stefan Schandelmaier; Sun Xin; Per Olav Vandvik

IMPORTANCE The discontinuation of randomized clinical trials (RCTs) raises ethical concerns and often wastes scarce research resources. The epidemiology of discontinued RCTs, however, remains unclear. OBJECTIVES To determine the prevalence, characteristics, and publication history of discontinued RCTs and to investigate factors associated with RCT discontinuation due to poor recruitment and with nonpublication. DESIGN AND SETTING Retrospective cohort of RCTs based on archived protocols approved by 6 research ethics committees in Switzerland, Germany, and Canada between 2000 and 2003. We recorded trial characteristics and planned recruitment from included protocols. Last follow-up of RCTs was April 27, 2013. MAIN OUTCOMES AND MEASURES Completion status, reported reasons for discontinuation, and publication status of RCTs as determined by correspondence with the research ethics committees, literature searches, and investigator surveys. RESULTS After a median follow-up of 11.6 years (range, 8.8-12.6 years), 253 of 1017 included RCTs were discontinued (24.9% [95% CI, 22.3%-27.6%]). Only 96 of 253 discontinuations (37.9% [95% CI, 32.0%-44.3%]) were reported to ethics committees. The most frequent reason for discontinuation was poor recruitment (101/1017; 9.9% [95% CI, 8.2%-12.0%]). In multivariable analysis, industry sponsorship vs investigator sponsorship (8.4% vs 26.5%; odds ratio [OR], 0.25 [95% CI, 0.15-0.43]; P < .001) and a larger planned sample size in increments of 100 (-0.7%; OR, 0.96 [95% CI, 0.92-1.00]; P = .04) were associated with lower rates of discontinuation due to poor recruitment. Discontinued trials were more likely to remain unpublished than completed trials (55.1% vs 33.6%; OR, 3.19 [95% CI, 2.29-4.43]; P < .001). CONCLUSIONS AND RELEVANCE In this sample of trials based on RCT protocols from 6 research ethics committees, discontinuation was common, with poor recruitment being the most frequently reported reason. Greater efforts are needed to ensure the reporting of trial discontinuation to research ethics committees and the publication of results of discontinued trials.


PLOS ONE | 2012

Return to work coordination programmes for work disability: a meta-analysis of randomised controlled trials.

Stefan Schandelmaier; Shanil Ebrahim; Susan C. A. Burkhardt; Wout de Boer; Thomas Zumbrunn; Gordon H. Guyatt; Jason W. Busse; Regina Kunz

Background The dramatic rise in chronically ill patients on permanent disability benefits threatens the sustainability of social security in high-income countries. Social insurance organizations have started to invest in promising, but costly return to work (RTW) coordination programmes. The benefit, however, remains uncertain. We conducted a systematic review to determine the long-term effectiveness of RTW coordination compared to usual practice in patients at risk for long-term disability. Methods and Findings Eligible trials enrolled employees on work absence for at least 4 weeks and randomly assigned them to RTW coordination or to usual practice. We searched 5 databases (to April 2, 2012). Two investigators performed standardised eligibility assessment, study appraisal and data extraction independently and in duplicate. The GRADE framework guided our assessment of confidence in the meta-analytic estimates. We identified 9 trials from 7 countries, 8 focusing on musculoskeletal, and 1 on mental complaints. Most trials followed participants for 12 months or less. No trial assessed permanent disability. Moderate quality evidence suggests a benefit of RTW coordination on proportion at work at end of follow-up (risk ratio = 1.08, 95% CI = 1.03 to 1.13; absolute effect = 5 in 100 additional individuals returning to work, 95% CI = 2 to 8), overall function (mean difference [MD] on a 0 to 100 scale = 5.2, 95% CI = 2.4 to 8.0; minimal important difference [MID] = 10), physical function (MD = 5.3, 95% CI = 1.4 to 9.1; MID = 8.4), mental function (MD = 3.1, 95% CI = 0.7 to 5.6; MID = 7.3) and pain (MD = 6.1, 95% CI = 3.1 to 9.2; MID = 10). Conclusions Moderate quality evidence suggests that RTW coordination results in small relative, but likely important absolute benefits in the likelihood of disabled or sick-listed patients returning to work, and associated small improvements in function and pain. Future research should explore whether the limited effects persist, and whether the programmes are cost effective in the long term.


BMJ | 2014

Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications

Benjamin Kasenda; Stefan Schandelmaier; Xin Sun; Erik von Elm; John J. You; Anette Blümle; Yuki Tomonaga; Ramon Saccilotto; Alain Amstutz; Theresa Bengough; Joerg J. Meerpohl; Mihaela Stegert; Kelechi K Olu; Kari A.O. Tikkinen; Ignacio Neumann; Alonso Carrasco-Labra; Markus Faulhaber; Sohail Mulla; Dominik Mertz; Elie A. Akl; Dirk Bassler; Jason W. Busse; Ignacio Ferreira-González; Francois Lamontagne; Alain Nordmann; Viktoria Gloy; Heike Raatz; Lorenzo Moja; Rachel Rosenthal; Shanil Ebrahim

Objective To investigate the planning of subgroup analyses in protocols of randomised controlled trials and the agreement with corresponding full journal publications. Design Cohort of protocols of randomised controlled trial and subsequent full journal publications. Setting Six research ethics committees in Switzerland, Germany, and Canada. Data sources 894 protocols of randomised controlled trial involving patients approved by participating research ethics committees between 2000 and 2003 and 515 subsequent full journal publications. Results Of 894 protocols of randomised controlled trials, 252 (28.2%) included one or more planned subgroup analyses. Of those, 17 (6.7%) provided a clear hypothesis for at least one subgroup analysis, 10 (4.0%) anticipated the direction of a subgroup effect, and 87 (34.5%) planned a statistical test for interaction. Industry sponsored trials more often planned subgroup analyses compared with investigator sponsored trials (195/551 (35.4%) v 57/343 (16.6%), P<0.001). Of 515 identified journal publications, 246 (47.8%) reported at least one subgroup analysis. In 81 (32.9%) of the 246 publications reporting subgroup analyses, authors stated that subgroup analyses were prespecified, but this was not supported by 28 (34.6%) corresponding protocols. In 86 publications, authors claimed a subgroup effect, but only 36 (41.9%) corresponding protocols reported a planned subgroup analysis. Conclusions Subgroup analyses are insufficiently described in the protocols of randomised controlled trials submitted to research ethics committees, and investigators rarely specify the anticipated direction of subgroup effects. More than one third of statements in publications of randomised controlled trials about subgroup prespecification had no documentation in the corresponding protocols. Definitive judgments regarding credibility of claimed subgroup effects are not possible without access to protocols and analysis plans of randomised controlled trials.


Annals of Surgery | 2015

Completion and publication rates of randomized controlled trials in surgery: an empirical study

Rachel Rosenthal; Benjamin Kasenda; Salome Dell-Kuster; Erik von Elm; John J. You; Anette Blümle; Yuki Tomonaga; Ramon Saccilotto; Alain Amstutz; Theresa Bengough; Joerg J. Meerpohl; Mihaela Stegert; Kari A.O. Tikkinen; Ignacio Neumann; Alonso Carrasco-Labra; Markus Faulhaber; Sohail Mulla; Dominik Mertz; Elie A. Akl; Dirk Bassler; Jason W. Busse; Ignacio Ferreira-González; Francois Lamontagne; Alain Nordmann; Viktoria Gloy; Kelechi K Olu; Heike Raatz; Lorenzo Moja; Shanil Ebrahim; Stefan Schandelmaier

OBJECTIVE To investigate the prevalence of discontinuation and nonpublication of surgical versus medical randomized controlled trials (RCTs) and to explore risk factors for discontinuation and nonpublication of surgical RCTs. BACKGROUND Trial discontinuation has significant scientific, ethical, and economic implications. To date, the prevalence of discontinuation of surgical RCTs is unknown. METHODS All RCT protocols approved between 2000 and 2003 by 6 ethics committees in Canada, Germany, and Switzerland were screened. Baseline characteristics were collected and, if published, full reports retrieved. Risk factors for early discontinuation for slow recruitment and nonpublication were explored using multivariable logistic regression analyses. RESULTS In total, 863 RCT protocols involving adult patients were identified, 127 in surgery (15%) and 736 in medicine (85%). Surgical trials were discontinued for any reason more often than medical trials [43% vs 27%, risk difference 16% (95% confidence interval [CI]: 5%-26%); P = 0.001] and more often discontinued for slow recruitment [18% vs 11%, risk difference 8% (95% CI: 0.1%-16%); P = 0.020]. The percentage of trials not published as full journal article was similar in surgical and medical trials (44% vs 40%, risk difference 4% (95% CI: -5% to 14%); P = 0.373). Discontinuation of surgical trials was a strong risk factor for nonpublication (odds ratio = 4.18, 95% CI: 1.45-12.06; P = 0.008). CONCLUSIONS Discontinuation and nonpublication rates were substantial in surgical RCTs and trial discontinuation was strongly associated with nonpublication. These findings need to be taken into account when interpreting surgical literature. Surgical trialists should consider feasibility studies before embarking on full-scale trials.


BMC Medical Research Methodology | 2012

Learning from failure - rationale and design for a study about discontinuation of randomized trials (DISCO study)

Benjamin Kasenda; Erik von Elm; John J. You; Anette Blümle; Yuki Tomonaga; Ramon Saccilotto; Alain Amstutz; Theresa Bengough; Jörg J. Meerpohl; Mihaela Stegert; Kari A.O. Tikkinen; Ignacio Neumann; Alonso Carrasco-Labra; Markus Faulhaber; Sohail Mulla; Dominik Mertz; Elie A. Akl; Dirk Bassler; Jason W. Busse; Ignacio Ferreira-González; Francois Lamontagne; Alain Nordmann; Rachel Rosenthal; Stefan Schandelmaier; Xin Sun; Per Olav Vandvik; Bradley C. Johnston; Martin A. Walter; Bernard Burnand; Matthias Schwenkglenks

BackgroundRandomized controlled trials (RCTs) may be discontinued because of apparent harm, benefit, or futility. Other RCTs are discontinued early because of insufficient recruitment. Trial discontinuation has ethical implications, because participants consent on the premise of contributing to new medical knowledge, Research Ethics Committees (RECs) spend considerable effort reviewing study protocols, and limited resources for conducting research are wasted. Currently, little is known regarding the frequency and characteristics of discontinued RCTs.Methods/DesignOur aims are, first, to determine the prevalence of RCT discontinuation for specific reasons; second, to determine whether the risk of RCT discontinuation for specific reasons differs between investigator- and industry-initiated RCTs; third, to identify risk factors for RCT discontinuation due to insufficient recruitment; fourth, to determine at what stage RCTs are discontinued; and fifth, to examine the publication history of discontinued RCTs.We are currently assembling a multicenter cohort of RCTs based on protocols approved between 2000 and 2002/3 by 6 RECs in Switzerland, Germany, and Canada. We are extracting data on RCT characteristics and planned recruitment for all included protocols. Completion and publication status is determined using information from correspondence between investigators and RECs, publications identified through literature searches, or by contacting the investigators. We will use multivariable regression models to identify risk factors for trial discontinuation due to insufficient recruitment. We aim to include over 1000 RCTs of which an anticipated 150 will have been discontinued due to insufficient recruitment.DiscussionOur study will provide insights into the prevalence and characteristics of RCTs that were discontinued. Effective recruitment strategies and the anticipation of problems are key issues in the planning and evaluation of trials by investigators, Clinical Trial Units, RECs and funding agencies. Identification and modification of barriers to successful study completion at an early stage could help to reduce the risk of trial discontinuation, save limited resources, and enable RCTs to better meet their ethical requirements.


Journal of Clinical Epidemiology | 2016

A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable

Matthias Briel; Kelechi K Olu; Erik von Elm; Benjamin Kasenda; Reem Alturki; Arnav Agarwal; Neera Bhatnagar; Stefan Schandelmaier

OBJECTIVE To collect and classify reported reasons for recruitment failure in discontinued randomized controlled trials (RCTs) and to assess reporting quality. METHODS We systematically searched MEDLINE and EMBASE (2010-2014) and a previous cohort of RCTs for published RCTs reporting trial discontinuation due to poor recruitment. Teams of two investigators selected eligible RCTs working independently and extracted information using standardized forms. We used an iterative approach to classify reasons for poor recruitment. RESULTS We included 172 RCTs discontinued due to poor recruitment (including 26 conference abstracts and 63 industry-funded RCTs). Of those, 131 (76%) reported one or more reasons for discontinuation due to poor recruitment. We identified 28 different reasons for recruitment failure; most frequently mentioned were overestimation of prevalence of eligible participants and prejudiced views of recruiters and participants on trial interventions. Few RCTs reported relevant details about the recruitment process such as how eligible participants were identified, the number of patients assessed for eligibility, and who actually recruited participants. CONCLUSION Our classification could serve as a checklist to assist investigators in the planning of RCTs. Most reasons for recruitment failure seem preventable with a pilot study that applies the planned informed consent procedure.


BMJ Open | 2017

Knee arthroscopy versus conservative management in patients with degenerative knee disease: a systematic review

Romina Brignardello-Petersen; Gordon H. Guyatt; Rachelle Buchbinder; Rudolf W. Poolman; Stefan Schandelmaier; Yaping Chang; Behnam Sadeghirad; Nathan Evaniew; Per Olav Vandvik

Objective To determine the effects and complications of arthroscopic surgery compared with conservative management strategies in patients with degenerative knee disease. Design Systematic review. Main outcome measures Pain, function, adverse events. Data sources MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Google Scholar and Open Grey up to August 2016. Eligibility criteria For effects, randomised clinical trials (RCTs) comparing arthroscopic surgery with a conservative management strategy (including sham surgery) in patients with degenerative knee disease. For complications, RCTs and observational studies. Review methods Two reviewers independently extracted data and assessed risk of bias for patient-important outcomes. A parallel guideline committee (BMJ Rapid Recommendations) provided input on the design and interpretation of the systematic review, including selection of patient-important outcomes. We used the GRADE approach to rate the certainty (quality) of the evidence. Results We included 13 RCTs and 12 observational studies. With respect to pain, the review identified high-certainty evidence that knee arthroscopy results in a very small reduction in pain up to 3 months (mean difference =5.4 on a 100-point scale, 95% CI 2.0 to 8.8) and very small or no pain reduction up to 2 years (mean difference =3.1, 95% CI −0.2 to 6.4) when compared with conservative management. With respect to function, the review identified moderate-certainty evidence that knee arthroscopy results in a very small improvement in the short term (mean difference =4.9 on a 100-point scale, 95% CI 1.5 to 8.4) and very small or no improved function up to 2 years (mean difference =3.2, 95% CI −0.5 to 6.8). Alternative presentations of magnitude of effect, and associated sensitivity analyses, were consistent with the findings of the primary analysis. Low-quality evidence suggested a very low probability of serious complications after knee arthroscopy. Conclusions Over the long term, patients who undergo knee arthroscopy versus those who receive conservative management strategies do not have important benefits in pain or function. Trial registration number PROSPERO CRD42016046242.


Systematic Reviews | 2013

Systematic review and network meta-analysis of interventions for fibromyalgia: a protocol

Jason W. Busse; Shanil Ebrahim; Gaelan Connell; Eric A. Coomes; Paul Bruno; Keshena Malik; David Torrance; Trung Ngo; Karin Kirmayr; Daniel Avrahami; John J. Riva; Peter Struijs; David Brunarski; Stephen J. Burnie; Frances LeBlanc; Ivan Steenstra; Quenby Mahood; Kristian Thorlund; Victor M. Montori; Vishalini Sivarajah; Paul E. Alexander; Milosz Jankowski; Wiktoria Lesniak; Markus Faulhaber; Malgorzata M Bala; Stefan Schandelmaier; Gordon H. Guyatt

BackgroundFibromyalgia is associated with substantial socioeconomic loss and, despite considerable research including numerous randomized controlled trials (RCTs) and systematic reviews, there exists uncertainty regarding what treatments are effective. No review has evaluated all interventional studies for fibromyalgia, which limits attempts to make inferences regarding the relative effectiveness of treatments.Methods/designWe will conduct a network meta-analysis of all RCTs evaluating therapies for fibromyalgia to determine which therapies show evidence of effectiveness, and the relative effectiveness of these treatments. We will acquire eligible studies through a systematic search of CINAHL, EMBASE, MEDLINE, AMED, HealthSTAR, PsychINFO, PapersFirst, ProceedingsFirst, and the Cochrane Central Registry of Controlled Trials. Eligible studies will randomly allocate patients presenting with fibromyalgia or a related condition to an intervention or a control. Teams of reviewers will, independently and in duplicate, screen titles and abstracts and complete full text reviews to determine eligibility, and subsequently perform data abstraction and assess risk of bias of eligible trials. We will conduct meta-analyses to establish the effect of all reported therapies on patient-important outcomes when possible. To assess relative effects of treatments, we will construct a random effects model within the Bayesian framework using Markov chain Monte Carlo methods.DiscussionOur review will be the first to evaluate all treatments for fibromyalgia, provide relative effectiveness of treatments, and prioritize patient-important outcomes with a focus on functional gains. Our review will facilitate evidence-based management of patients with fibromyalgia, identify key areas for future research, and provide a framework for conducting large systematic reviews involving indirect comparisons.


Pain | 2015

Reporting of IMMPACT-recommended core outcome domains among trials assessing opioids for chronic non-cancer pain.

Sohail Mulla; Amna Maqbool; Laxsanaa Sivananthan; Luciane Cruz Lopes; Stefan Schandelmaier; Mostafa Kamaleldin; Sandy Huey-Jen Hsu; John J. Riva; Per Olav Vandvik; Ludwig Tsoi; Tommy Shing Kit Lam; Shanil Ebrahim; Bradley C. Johnston; Lori Olivieri; Luis Montoya; Regina Kunz; Anne Scheidecker; D. Norman Buckley; Daniel I. Sessler; Gordon H. Guyatt; Jason W. Busse

Abstract The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) has recommended that trialists evaluating treatments for chronic pain should consider reporting 9 patient-important outcome domains. We examined the extent to which clinical trials evaluating the effect of opioids for chronic non-cancer pain (CNCP) report outcome domains recommended by IMMPACT. We systematically searched electronic databases for English-language studies that randomized patients with CNCP to receive an opioid or a non-opioid control. In duplicate and independently, reviewers established the eligibility of each identified study and recorded all reported outcome domains from eligible trials. We conducted a priori regression analyses to explore factors that may be associated with IMMPACT-recommended outcome domains. Among 156 eligible trials, reporting of IMMPACT-recommended outcome domains was highly variable, ranging from 99% for pain to 7% for interpersonal functioning. Recently published trials were more likely to report the effect of treatment on physical functioning, emotional functioning, role functioning, sleep and fatigue, and participant disposition. Trials for which the corresponding author was from North America were more likely to report treatment effects on physical functioning and participant ratings of improvement and satisfaction with treatment. Trials published in higher impact journals were more likely to report treatment effects on emotional function, but less likely to report participant ratings of improvement and satisfaction with treatment. Most IMMPACT domains showed an increased rate of reporting over time, although many patient-important outcome domains remained unreported by over half of all trials evaluating the effects of opioids for CNCP.


BMJ | 2017

Low intensity pulsed ultrasound (LIPUS) for bone healing: a clinical practice guideline

Rudolf W. Poolman; Thomas Agoritsas; Reed A C Siemieniuk; Ian A. Harris; Inger B. Schipper; Brent Mollon; Maureen Smith; Alexandra Albin; Sally Nador; Will Sasges; Stefan Schandelmaier; Lyubov Lytvyn; Ton Kuijpers; Loes W.A.H. van Beers; M.H.J. Verhofstad; Per Olav Vandvik

Does low intensity pulsed ultrasound (LIPUS) accelerate recovery in adults and children who have experienced bone fractures or osteotomy (cutting of a bone)? An expert panel rapidly produced these recommendations based on a linked systematic review triggered by a large multicentre randomised trial in adults with tibial fracture.

Collaboration


Dive into the Stefan Schandelmaier's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alain Amstutz

University Hospital of Basel

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kelechi K Olu

University Hospital of Basel

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge